Total Valuation
Zealand Pharma has a market cap or net worth of kr21.75B. The enterprise value is kr6.45K.
Market Capkr21.75B
Enterprise Valuekr6.45K
Share Statistics
Zealand Pharma has 71,578,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,578,760
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Zealand Pharma’s return on equity (ROE) is 0.44 and return on invested capital (ROIC) is 41.71%.
Return on Equity (ROE)0.44
Return on Assets (ROA)0.39
Return on Invested Capital (ROIC)41.71%
Return on Capital Employed (ROCE)0.45
Revenue Per Employee15.94M
Profits Per Employee11.17M
Employee Count578
Asset Turnover0.56
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Zealand Pharma is 7.8. Zealand Pharma’s PEG ratio is ―.
PE Ratio7.8
PS Ratio0.00
PB Ratio0.00
Price to Fair Value2.22
Price to FCF0.00
Price to Operating Cash Flow-12.26
PEG Ratio―
Income Statement
In the last 12 months, Zealand Pharma had revenue of 9.21B and earned 6.46B in profits. Earnings per share was 91.56.
Revenue9.21B
Gross Profit9.19B
Operating Income7.16B
Pretax Income7.00B
Net Income6.46B
EBITDA7.18B
Earnings Per Share (EPS)91.56
Cash Flow
In the last 12 months, operating cash flow was -1.75B and capital expenditures -44.49M, giving a free cash flow of -1.80B billion.
Operating Cash Flow-1.75B
Free Cash Flow-1.80B
Free Cash Flow per Share-25.11
Dividends & Yields
Zealand Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.70
52-Week Price Change-30.89%
50-Day Moving Average307.31
200-Day Moving Average353.85
Relative Strength Index (RSI)46.52
Average Volume (3m)32.15K
Important Dates
Zealand Pharma upcoming earnings date is Nov 12, 2026, TBA (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 12, 2026
Ex-Dividend Date―
Financial Position
Zealand Pharma as a current ratio of 23.57, with Debt / Equity ratio of 2.28%
Current Ratio23.57
Quick Ratio23.57
Debt to Market Cap<0.01
Net Debt to EBITDA-0.58
Interest Coverage Ratio189.81
Taxes
In the past 12 months, Zealand Pharma has paid 546.06M in taxes.
Income Tax546.06M
Effective Tax Rate0.08
Enterprise Valuation
Zealand Pharma EV to EBITDA ratio is 4.00, with an EV/FCF ratio of 4.42.
EV to Sales3.12
EV to EBITDA4.00
EV to Free Cash Flow4.42
EV to Operating Cash Flow4.40
Balance Sheet
Zealand Pharma has kr14.46B in cash and marketable securities with kr394.64M in debt, giving a net cash position of kr14.05B billion.
Cash & Marketable Securitieskr14.46B
Total Debtkr394.64M
Net Cashkr14.05B
Net Cash Per Sharekr196.23
Tangible Book Value Per Sharekr209.72
Margins
Gross margin is 99.22%, with operating margin of 77.66%, and net profit margin of 70.05%.
Gross Margin99.22%
Operating Margin77.66%
Pretax Margin75.98%
Net Profit Margin70.05%
EBITDA Margin77.95%
EBIT Margin77.66%
Analyst Forecast
The average price target for Zealand Pharma is kr351.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Targetkr351.67
Price Target Upside15.34% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-49.03%
EPS Growth Forecast-58.96%